These results indicate that TBK1/IKKε inhibitors may offer a novel therapeutic approach to reduce YAP/TAZ activation and attenuate PASMC activation and downstream vascular remodeling in PAH. Here, TBK1 is linked to pulmonary arterial hypertension.